Sekar Kathiresan showcases historic monkey data in hunt for a once-and-done gene editing approach to prevent heart attacks
In a first for CRISPR — a field that’s seen quite a few historic moves in the past couple of years — scientists have slashed cholesterol and lipid levels in monkeys using a technique known as base editing, generating crucial proof-of-concept for both the biotech behind the experiment and a key partner.
Verve Therapeutics designed two similar experiments to test whether they can reproduce protective mutations in a pair of genes using an adenine base editor, which precisely alters a chosen A to a G in the genome. CEO and co-founder Sekar Kathiresan presented the results at a virtual keynote for the International Society for Stem Cell Research over the weekend.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.